HLB Life Science Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 02:21 am EDT
Share
HLB Life Science Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 15,868.22 million compared to KRW 13,648.91 million a year ago. Net income was KRW 6,594.74 million compared to net loss of KRW 16,616.5 million a year ago. Basic earnings per share from continuing operations was KRW 65.6082 compared to basic loss per share from continuing operations of KRW 167.3484 a year ago. Diluted earnings per share from continuing operations was KRW 65.6082 compared to diluted loss per share from continuing operations of KRW 167.3484 a year ago. Basic earnings per share was KRW 65.6082 compared to basic loss per share of KRW 167.3484 a year ago.
For the six months, sales was KRW 200.39 million compared to KRW 256.11 million a year ago. Net loss was KRW 3,772.76 million compared to KRW 32,090.44 million a year ago. Basic loss per share from continuing operations was KRW 38.0337 compared to KRW 324.2375 a year ago. Diluted loss per share from continuing operations was KRW 38.0337 compared to KRW 324.2375 a year ago. Basic loss per share was KRW 38.0337 compared to KRW 324.2375 a year ago.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
HLB LIFE SCIENCE CO., LTD. 
